Prescriber Scope of Practice for General Psychiatry in New York

If you’re a psychiatrist, PMHNP, or other prescriber wondering whether you can legally prescribe ADHD medications, benzodiazepines, or other controlled substances through telehealth — you’re not alone. The rules have been changing constantly since COVID, and the uncertainty is real.

Here’s the bottom line as of early 2026: Yes, you can prescribe controlled substances via telehealth to new patients without an in-person visit — but only through December 31, 2026, under a federal extension. After that, new permanent DEA rules will likely kick in, changing how telepsychiatry prescribing works.

This guide breaks down exactly what psychiatrists and PMHNPs need to know about federal DEA regulations, state-by-state telehealth laws, scope of practice differences, and what’s coming next. No fluff — just the regulatory facts that affect your practice and income.

Federal DEA Rules: Where We Stand in 2026

The Current Extension (Through December 31, 2026)

The DEA and HHS just announced their fourth temporary extension of COVID-era telehealth flexibilities for controlled substances. This means through the end of 2026, you can:

• Prescribe Schedule II–V controlled substances via telehealth to new patients you’ve never seen in person
• Conduct the initial evaluation via live audio-video (not just phone, except for specific buprenorphine cases)
• Continue treating existing telehealth patients without any new in-person requirement

What this means practically: A psychiatrist can evaluate a new ADHD patient via video consultation and prescribe Adderall (Schedule II) on the same day. A PMHNP can start a patient on clonazepam (Schedule IV) for panic disorder after a thorough telehealth assessment. No in-person visit required — yet.

The catch? This is explicitly temporary. The extension exists ‘while permanent rules are finalized.’ The DEA has made clear that new regulations are coming.

What Permanent Rules Are Coming?

In January 2025, the DEA proposed three new telemedicine rules that will reshape psychiatric prescribing:

1. Buprenorphine for Opioid Use Disorder
Providers could prescribe buprenorphine via telehealth (including audio-only) for up to 6 months before requiring an in-person visit. This is huge for addiction psychiatry — it formalizes what many providers have been doing and removes barriers to MAT. After 6 months of treatment, one in-person evaluation would be required to continue.

2. Special Telemedicine Registration for Controlled Substances
The DEA proposes creating a ‘Special Telemedicine Prescriber Registration’ that would allow qualified providers to prescribe controlled substances to new patients via telehealth without ever seeing them in person.

Here’s what matters for psychiatrists:

• For Schedule III–V medications (most benzodiazepines, some stimulants like Vyvanse), any DEA-registered provider could apply for this special registration
• For Schedule II medications (Adderall, Ritalin, Concerta), the DEA is initially limiting eligibility to board-certified psychiatrists, hospice/palliative care physicians, long-term care facility physicians, and pediatricians
• Psychiatric NPs are notably absent from the Schedule II eligibility list in the current proposal (though they could still prescribe Schedule III–V with the registration)

What this means: If you’re a board-certified psychiatrist, you’d likely be able to continue tele-prescribing ADHD medications indefinitely under a special registration. If you’re a PMHNP, you might face new restrictions on Schedule II prescribing via telehealth once permanent rules take effect.

3. Platform Registration & National PDMP
For the first time, online telehealth platforms would have to register with the DEA. The rule also calls for a national Prescription Drug Monitoring Program to track controlled substance prescriptions across state lines.

This is the DEA’s response to cases where telehealth companies were found to be over-prescribing stimulants without adequate oversight. Legitimate platforms will comply easily; it mainly adds accountability.

The Ryan Haight Act Background

All of this stems from the Ryan Haight Act of 2008, which made it illegal to prescribe controlled substances via the internet without at least one in-person medical evaluation. The law was intended to stop ‘pill mills’ operating through online questionnaires.

The problem? The law included an exception for providers with a ‘special DEA telemedicine registration’ — but the DEA never created that registration process. For over a decade, telemedicine prescribing of controlled substances was essentially blocked.

COVID changed everything. Federal emergency authority suspended the in-person requirement in March 2020, and telepsychiatry exploded. Now, with the emergency over, the DEA is finally building the regulatory framework the Ryan Haight Act envisioned.

Bottom line: The current temporary extension gives you certainty through 2026. After that, you’ll likely need either an in-person visit with new patients OR the new special telemedicine registration to continue prescribing Schedule II medications via telehealth.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Critical Compliance Requirements (Federal)

Regardless of the temporary waivers, certain federal requirements apply right now:

1. Use Real-Time Audio-Video Communication

For prescribing controlled substances to new patients, you must conduct a live video evaluation. Audio-only (telephone) doesn’t meet the standard for most controlled substances, with one exception: buprenorphine for opioid use disorder can be prescribed after an audio-only consult under current DEA guidance.

For follow-up appointments with established patients, some flexibility exists — but initial controlled substance prescribing demands video.

2. State PDMP Checks

Most states require you to check their Prescription Drug Monitoring Program before prescribing controlled substances. Requirements vary:

• California: Check CURES before first Schedule II–IV prescription and every 4 months during ongoing treatment
• Texas: Mandatory for opioids, benzodiazepines, barbiturates, and carisoprodol
• Florida: Required for any controlled substance for patients 16+
• New York: Required for every Schedule II, III, or IV prescription (one of the strictest)
• Pennsylvania: Required before first opioid or benzodiazepine prescription
• Illinois: Required each time before prescribing opioids

Missing a PDMP check can result in board discipline. Make it standard practice.

3. E-Prescribing Mandates

Federal Medicare rules require e-prescribing for controlled substances (with limited exceptions). Most states have their own e-prescribing mandates:

• California: All prescriptions must be electronic (2022)
• New York: All prescriptions electronic since 2016
• Texas, Florida, Pennsylvania, Illinois: E-prescribing required for controlled substances

Telehealth platforms handle this automatically, but if you’re building your own practice, you need a HIPAA-compliant, DEA-approved e-prescribing system with two-factor authentication.

4. New DEA Training Requirement

As of June 2023, all DEA registrants must complete 8 hours of training on substance use disorder and appropriate prescribing of opioids and other controlled substances. This is a one-time requirement but is verified at DEA license renewal.

Board-certified addiction psychiatrists are exempt (their specialty credential counts). Most psychiatrists likely covered this in residency, but you still need to document it for DEA purposes.

The training must cover at least one of the following: appropriate use of controlled substances, pain management, or identifying/treating substance use disorders.

Psychiatrist vs PMHNP: Scope of Practice Differences That Matter

This is where things get complicated — and where your income potential and practice model can vary dramatically based on which state you’re in.

Psychiatrists (MD/DO): Full Authority Everywhere

If you’re a licensed psychiatrist, your scope is straightforward: full independent practice in all 50 states. You can diagnose any psychiatric condition and prescribe any medication within your clinical expertise, including all Schedule II–V controlled substances.

The only requirements:

• State medical license where the patient is located
• DEA registration in that state
• Compliance with state and federal prescribing rules

No supervision needed. No collaborative agreements. No practice hour thresholds. A Texas psychiatrist has the same prescriptive authority as one in New York or California.

PMHNPs: It Depends Entirely on the State

Psychiatric Mental Health Nurse Practitioners face a patchwork of state regulations that directly impact what they can do on a telehealth platform. Let’s break down our priority states:

New York — Full Practice After 3,600 Hours

New York modernized its NP laws in 2022. Once a PMHNP completes 3,600 clinical practice hours, they can practice completely independently — no collaborative agreement with a physician required.

This means an experienced New York PMHNP can:

• Evaluate and diagnose patients independently
• Prescribe all medications including Schedule II–V controlled substances
• Run their own telehealth practice without any physician involvement

New PMHNPs (under 3,600 hours) still need a written collaborative agreement with a physician, but it’s mainly a formality for the first couple of years.

For telehealth platforms: New York is an ideal state for recruiting experienced PMHNPs. They have full autonomy and can handle the same patient load as psychiatrists.

California — Transitioning to Full Practice

California passed AB-890 in 2020, creating a phased pathway to NP independence. Here’s where things stand in 2026:

• As of 2023: PMHNPs with ≥3 years of supervised experience can practice without physician oversight in group practices or clinics (Category 103)
• Starting 2024-2026: Those experienced NPs can apply for full independent practice authority (Category 104), allowing them to open private practices without any physician on-site

The first cohort of fully independent California PMHNPs is emerging in 2026. This is a massive shift for a state that previously required physician collaboration.

Current reality: Most California PMHNPs still have a collaborating psychiatrist on paper as of early 2026, but that’s changing fast. By 2027, expect California to look more like New York in terms of NP autonomy.

Texas — Highly Restricted

Texas is one of the toughest states for nurse practitioners. PMHNPs in Texas face two major limitations:

1. Mandatory Physician Supervision
All Texas NPs must have a written supervisory agreement with a physician for all medical tasks. The physician doesn’t need to be on-site, but the relationship must be formal and documented.

2. Cannot Prescribe Schedule II Outside Hospitals/Hospice
This is the killer for telehealth: Texas law prohibits NPs and PAs from prescribing Schedule II controlled substances in outpatient settings.

The only exceptions:

• Patient is admitted to a hospital (≥24 hours or in the ER)
• Hospice care
• Affiliated with a hospital in specific circumstances

What this means practically: A Texas PMHNP cannot prescribe Adderall, Ritalin, Concerta, or other Schedule II stimulants to outpatient telehealth patients. If a patient needs ADHD medication, a physician must write that prescription.

Texas NPs can prescribe Schedule III–V medications (many benzodiazepines, Vyvanse/lisdexamfetamine, buprenorphine, etc.) under their collaborative agreement.

For telehealth platforms: In Texas, you need a hybrid model — PMHNPs for anxiety, depression, and some ADHD cases (if using non-Schedule II options), plus psychiatrists to handle Schedule II prescribing. Or you pair each NP with a supervising physician who can handle those scripts.

Florida — Restricted, But Psychiatric Exception Helps

Florida created autonomous practice licenses for some NPs in 2020, but psychiatric NPs were excluded. PMHNPs in Florida must have a protocol agreement with a supervising physician.

However, Florida has an important carve-out for telehealth: Schedule II controlled substances cannot be prescribed via telehealth EXCEPT for psychiatric treatment (plus inpatient, hospice, or nursing home care).

What this means:

• A Florida PMHNP can prescribe Adderall via telehealth if it’s for ADHD (psychiatric condition) — but only under physician supervision
• The psychiatric exception means mental health telehealth is more viable in Florida than, say, telehealth pain management
• Schedule III–V can be prescribed via telehealth freely (within scope)

Florida also has an out-of-state telehealth provider registration — out-of-state NPs can register to treat Florida patients without a Florida license, but they still need physician collaboration and face the same prescribing restrictions.

For platforms: Florida PMHNPs need physician oversight, but the psychiatric carve-out for Schedule II prescribing means they can still handle ADHD and other controlled substance cases via telehealth with proper supervision.

Illinois — Full Practice Available, With a Catch

Illinois offers a Full Practice Authority (FPA) license for experienced NPs. Requirements:

• 4,000 clinical practice hours
• 250 hours of continuing education/additional training
• National certification

Once a PMHNP has FPA, no collaborative agreement required for most practice.

The catch: Even with FPA, Illinois law requires NPs to enter a ‘consultation relationship’ with a physician to prescribe benzodiazepines or Schedule II opioids, and limits those to 30-day supplies.

The law’s wording is a bit ambiguous about whether this applies to Schedule II stimulants (Adderall, etc.) or just opioids. Many Illinois NPs interpret it as requiring physician consultation for any Schedule II, meaning ADHD prescribing would need MD involvement even with FPA.

For platforms: Illinois PMHNPs with FPA can operate mostly independently, but you may need a physician consult arrangement for stimulant prescribing to stay conservative with compliance.

Pennsylvania — Reduced Practice

Pennsylvania requires PMHNPs to maintain collaborative agreements with physicians for prescriptive authority. Regulations suggest having at least two physicians involved in the collaboration.

PA NPs can prescribe:

• Schedule II: Up to 30-day supply (then physician must evaluate patient)
• Schedule III-IV: Up to 90-day supply

NPs cannot practice fully independently. They’re not allowed to independently sign certain medical documents or join medical staff at hospitals.

For platforms: Pennsylvania PMHNPs need formal physician collaboration, but they can handle most psychiatric prescribing with quantity limits on Schedule II.

Summary Table: PMHNP Scope by State

State-by-State Telehealth Prescribing Rules

Beyond DEA federal law, each state adds its own layer of telehealth regulations. Here’s what matters for psychiatric prescribing in each priority state:

California

The Good:

• No state-level in-person exam requirement for telehealth prescribing
• A video evaluation meets the ‘appropriate exam’ standard
• No special restrictions on controlled substances via telehealth beyond federal law
• Joined the Interstate Medical Licensure Compact (easier multi-state licensing for MDs)

The Requirements:

• CURES PDMP mandatory: Check before first Schedule II–IV prescription, then every 4 months during treatment
• 100% e-prescribing required since January 2022 (few exceptions)
• Must follow same standard of care as in-person

The Nuance:

• California allows audio-only telehealth for reimbursement, but for controlled substance prescribing, standard of care demands video for new patient evaluations

Texas

The Good:

• 2017 law (S.B. 1107) explicitly allows physician-patient relationships via telemedicine without in-person meetings
• Mental health has specific protections — telepsychiatry evaluations via video are sufficient

The Challenges:

• Chronic pain prescribing via telehealth is prohibited — must have in-person evaluation for ongoing controlled substance pain management (doesn’t affect most psychiatric practice)
• Texas PMP mandatory: Must check before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol
• NP Schedule II restriction means you need MDs for stimulant prescriptions
• Must use interactive, real-time communication

For Out-of-State Providers:

• No special telehealth license — must get full Texas medical license
• Texas is in the IMLC (streamlines licensing for physicians)

Florida

The Unique Setup:

• Out-of-state telehealth provider registration available — physicians and NPs from other states can register to treat Florida patients without full Florida licensure
• Registration requires: proof of license in home state, no discipline, Florida agent designation, malpractice coverage

The Prescribing Rules:

• Schedule II CANNOT be prescribed via telehealth EXCEPT for:

1. Psychiatric disorder treatment ← This is your lane
2. Inpatient hospital care
3. Hospice care
4. Nursing home resident care

• Schedule III–V can be prescribed via telehealth freely
• E-FORCSE PDMP mandatory: Check before prescribing any controlled substance to patients 16+
• E-prescribing required for controlled substances

What This Means:

• A Florida psychiatrist (or registered out-of-state psychiatrist) can prescribe Adderall via telehealth for ADHD — it falls under ‘psychiatric disorder treatment’
• You CANNOT prescribe Schedule II for non-psychiatric uses via telehealth (e.g., pain management)
• Document the psychiatric indication clearly

The Catch:

• If using the out-of-state registration, you’re still limited by Florida scope rules — if you’re an NP, you need physician collaboration even with the telehealth registration

New York

The Good:

• Very telehealth-friendly state
• No state law requiring in-person exam before prescribing via telehealth
• Strong insurance parity laws for telehealth reimbursement
• Made some audio-only mental health services permanently reimbursable

The Requirements:

• I-STOP PDMP mandatory: Must check the Prescription Monitoring Program before EVERY Schedule II, III, or IV prescription (one of strictest in nation)
• All prescriptions must be electronic since 2016 (controlled and non-controlled)
• Must obtain informed consent for telehealth
• Full New York medical license required (not in IMLC yet)

For PMHNPs:

• Full practice authority after 3,600 hours — can prescribe independently including all controlled substances

Pennsylvania

The Current State:

• No comprehensive telehealth statute yet (bills have stalled)
• Medical board allows telehealth under general practice authority
• Telehealth exam can satisfy the ‘appropriate evaluation’ requirement

The Requirements:

• PA PMP mandatory: Check before prescribing opioids or benzodiazepines (initial and periodic)
• E-prescribing required for controlled substances (since 2019)
• Must have Pennsylvania medical license (no out-of-state telehealth without license)

The Gray Area:

• Because there’s no formal telehealth statute, providers operate under general medical practice rules
• Expected that future legislation will codify consent requirements and standards
• For now, follow standard of care and document thoroughly

Illinois

The Framework:

• Public Act 102-0104 (2021) established telehealth parity and same standard of care as in-person
• No in-person exam requirement if telehealth exam is clinically appropriate
• No Illinois-specific prohibition on telehealth prescribing of controlled substances

The Requirements:

• IL PMP mandatory: Check before prescribing opioids each time (encouraged for other controlled substances)
• E-prescribing required for all controlled substances (since January 2023)
• Mental Health and Developmental Disabilities Confidentiality Act requires special consent for mental health records (applies to telehealth documentation)

For Licensing:

• Illinois is in the IMLC (MDs can get licensed more easily)
• Out-of-state providers allowed to do telehealth if properly licensed

The Economics: Why This Matters for Your Income

Here’s where regulatory knowledge translates to revenue.

Multi-State Licensing = Larger Patient Pool

Understanding these state-specific rules allows you to expand strategically:

• A psychiatrist with licenses in New York, California, and Texas can serve patients across three major markets
• An experienced PMHNP with New York and California licenses (or soon-to-be independent CA status) can practice with near-psychiatrist autonomy
• States in the IMLC make it faster and cheaper for psychiatrists to add licenses

The calculation: If you’re currently licensed in one state and see 80 patients/month, adding 2-3 states with streamlined IMLC licensing could let you serve 200+ patients without changing your schedule — you just expand your geographic reach via telehealth.

Avoiding States That Don’t Match Your Credentials

If you’re a PMHNP, some states aren’t worth the hassle:

• Texas: Unless a platform provides physician supervision for you, the Schedule II restriction limits your patient types (can’t handle ADHD independently)
• Florida: Requires physician collaboration — only makes sense if joining a platform that provides that infrastructure

But states like New York and California (by 2027) offer full income potential for experienced PMHNPs without needing physician oversight.

The Platform Advantage: Klarity Handles State Compliance

Here’s the real economics of going solo vs. joining a platform:

DIY Multi-State Practice Costs:

• Medical licenses: $500-2,000 per state (initial + renewals)
• DEA registrations: $731 per state every 3 years
• State PDMP registrations: Often required separately
• Malpractice insurance: $3,000-15,000/year (higher for multi-state)
• E-prescribing platform: $100-500/month
• HIPAA-compliant telehealth platform: $50-300/month
• Legal/compliance review: $2,000-10,000 for multi-state setup
• Time cost: 40-100+ hours managing applications, renewals, compliance

Most importantly: you’re spending time on administrative work instead of seeing patients.

Klarity’s Model:

• Pre-qualified patients matched to your specialty and availability
• Telehealth infrastructure included (HIPAA-compliant, integrated with e-prescribing)
• Compliance support for state-specific requirements
• Pay-per-appointment model — no upfront costs or monthly fees
• Both insurance and cash-pay patient flow
• You focus on clinical work; Klarity handles operations

When you factor in the opportunity cost of spending dozens of hours on credentialing and compliance vs. seeing patients at $150-300+ per appointment, the math is clear: platforms that handle infrastructure remove both financial risk and time waste.

For psychiatrists adding states, Klarity’s model means you can practice in 5-10 states without managing 5-10 sets of licenses, DEA numbers, PDMP registrations, and compliance protocols yourself — the platform ensures you’re meeting requirements while you maintain control of your schedule.

What’s Coming: Preparing for Post-2026 Changes

The December 31, 2026 extension deadline is real. Here’s how to prepare:

For Psychiatrists

If you’re board-certified:

• You’ll likely qualify for the new ‘Special Telemedicine Registration’ for Schedule II prescribing
• Budget for this new registration (cost TBD, likely similar to standard DEA fees)
• Be ready for potential new requirements (e.g., annual reporting, enhanced PDMP checks)

If you’re not board-certified:

• You may need to ensure at least one in-person visit with new patients before prescribing Schedule II via telehealth
• Or obtain board certification to qualify for special registration
• Schedule III–V prescribing should remain accessible via telehealth

For PMHNPs

The uncertainty:

• Current DEA proposals list board-certified psychiatrists for Schedule II special registration but don’t mention PMHNPs
• This could mean new in-person requirements for NPs prescribing stimulants, even in states where they have full practice authority

The strategy:

• If you’re in a full practice state (NY, eventually CA), you may still be able to prescribe Schedule III–V independently via telehealth
• For Schedule II (stimulants), you might need to partner with a psychiatrist or see patients in person initially
• Stay engaged with professional organizations (AANP, ANCC) that are advocating for NP inclusion in final rules

The opportunity:

• Focus on building strong relationships with supervising psychiatrists (even in independent practice states) to ensure you can continue Schedule II prescribing if rules tighten

For All Providers

Document everything now:

• Thorough intake evaluations for new telehealth patients
• Clear documentation of psychiatric diagnoses justifying controlled substance prescriptions
• Regular PDMP checks (document each one)
• Patient education about medication risks and monitoring plans

When DEA finalizes rules and state boards update guidance, providers with strong documentation practices will transition smoothly. Those who’ve been relying on loose standards will face scrutiny.

Stay informed:

• Follow DEA press releases and proposed rulemaking (regulations.gov)
• Monitor your state medical board and nursing board updates
• Join professional organizations that track regulatory changes

Frequently Asked Questions

Can I prescribe Adderall via telehealth in 2026?

Yes, through December 31, 2026, under the federal extension. After that, it depends:

• If you’re a board-certified psychiatrist, likely yes (via special registration)
• If you’re a PMHNP, unclear — the DEA proposal doesn’t include NPs in Schedule II special registration yet
• State rules also apply: In Texas, NPs can’t prescribe Schedule II outside hospitals regardless of federal law

Do I need an in-person visit before prescribing controlled substances via telehealth?

Not currently (through end of 2026). After that, you’ll need either:

• An in-person visit at some point, OR
• The new ‘Special Telemedicine Registration’ (if eligible), OR
• The patient had an in-person exam with any provider previously (satisfies Ryan Haight Act)

Can I use audio-only (telephone) for telehealth prescribing?

For most controlled substances, no — DEA guidance requires live audio-video for the evaluation.

Exception: Buprenorphine for opioid use disorder can be prescribed after audio-only consult under current rules, and the proposed 6-month buprenorphine rule would formalize this.

For follow-up appointments with established patients, some states allow audio-only for certain services, but best practice for controlled substances is video.

What states allow PMHNPs to prescribe controlled substances independently?

Full independence (no physician collaboration needed):

• New York (after 3,600 practice hours)
• California (transitioning — by 2026/2027 for experienced NPs)

Partial or pathway to independence:

• Illinois (with Full Practice Authority license, though physician consult needed for some Schedule II)

Restricted (physician collaboration always required):

• Texas (and cannot prescribe Schedule II outpatient)
• Florida (can prescribe Schedule II via telehealth for psych, but needs supervision)
• Pennsylvania (collaborative agreement required, 30-day limit on Schedule II)

Do I need a separate medical license for each state where I have telehealth patients?

Yes. Telehealth is considered to occur where the patient is located. You must be licensed in every state where your patients are physically present during consultations.

Exceptions:

• Interstate Medical Licensure Compact (IMLC) streamlines the process of obtaining multiple state licenses for physicians (not automatic — you still get individual licenses, just faster)
• Some states have out-of-state telehealth registration (like Florida) that allows limited practice without full licensure

If my state allows independent NP practice, can I prescribe controlled substances across state lines independently?

Only if:

1. The state where the patient is located allows independent NP practice
2. You have proper licensure/registration in that state
3. You meet that state’s specific requirements (PDMP, e-prescribing, etc.)

Your home state’s rules don’t travel with you. You must follow the rules of the state where the patient is located.

What’s the difference between the Ryan Haight Act and state telehealth laws?

Ryan Haight Act = Federal law (DEA) governing controlled substance prescribing via internet/telehealth. Sets the floor — minimum requirements all providers must meet.

State telehealth laws = State-specific rules that can be more restrictive but not more permissive than federal law. Examples:

• Florida bans Schedule II via telehealth except for psychiatric/hospice/hospital care
• Texas bans controlled substance prescribing for chronic pain via telehealth

You must comply with both federal and state law. When they differ, the stricter rule applies.

How do I check if a patient is ‘doctor shopping’ across state lines?

Use your state’s PDMP (Prescription Drug Monitoring Program). Most states now participate in interstate data sharing through PMP InterConnect or similar programs.

When you run a PDMP report, you can often see controlled substance prescriptions filled in neighboring states. Requirements vary:

• Some states mandate PDMP checks before every controlled Rx
• Others require it before initial prescription and periodically after
• A few states allow you to set up automated alerts if your patient gets prescriptions from other providers

Check your state medical board requirements for specifics.

Can I prescribe buprenorphine via telehealth?

Yes, and it’s actually easier than most controlled substances:

• No X-waiver required anymore (eliminated in 2023)
• Can use audio-only telehealth under current DEA guidance
• Proposed permanent rule would allow up to 6 months of treatment via telehealth before in-person visit required
• Must complete one-time 8-hour training on substance use disorder/pain management (MATE Act requirement for all DEA license renewals)

What happens if the DEA rules change while I’m treating a patient?

Generally, you’d be grandfathered for existing patient relationships. The DEA has historically not disrupted ongoing treatment when rules change.

However, best practice:

• Offer patients the option of an in-person visit if rules tighten
• Document thoroughly that you established care under the rules in effect at the time
• Consider requiring periodic in-person visits for high-dose or long-term controlled substance patients as conservative practice

The Smart Path Forward: Join a Platform That Handles Compliance

Here’s what we’ve covered: prescribing controlled substances via telehealth requires juggling federal DEA rules, state-by-state telehealth laws, scope of practice limitations, PDMP mandates, e-prescribing requirements, licensing in multiple states, and upcoming regulatory changes.

The reality: You can build this infrastructure yourself — get licensed in 5 states, register with each state’s PDMP, set up HIPAA-compliant telehealth and e-prescribing platforms, monitor regulatory updates, and maintain separate DEA registrations. It’s possible.

The economics: That setup costs $10,000-20,000+ in upfront expenses and 60-100+ hours of your time. Then you still need to find patients — which means spending another $3,000-5,000/month on marketing, with zero guarantee of ROI.

Or: Join a platform like Klarity Health that provides:

✅ Compliance infrastructure — PDMP integration, e-prescribing, HIPAA-compliant telehealth platform
✅ Pre-qualified patient flow — patients matched to your specialty, availability, and licensed states
✅ Multi-state support — guidance on licensing, credentialing, and state-specific requirements
✅ Zero upfront costs — pay-per-appointment model means you only pay when you see patients
✅ Both insurance and cash-pay — diverse patient revenue streams
✅ Regulatory monitoring — as rules change, the platform updates policies so you stay compliant

The choice isn’t really ‘platform vs independent practice.’ It’s ‘spend 40 hours/month on admin work vs 40 hours/month seeing patients.’

For psychiatrists: Klarity lets you practice across multiple states without managing the complexity of 5+ licenses, DEA numbers, and compliance protocols yourself.

For PMHNPs: Klarity provides the physician collaboration infrastructure required in restricted practice states (Texas, Florida, Pennsylvania) while giving you full autonomy in independent practice states (New York, California).

When DEA’s permanent rules drop in late 2026 or 2027, Klarity will handle the transition — updating credentialing, registration processes, and compliance protocols so you can keep seeing patients without interruption.

Ready to expand your telepsychiatry practice without the compliance headaches? Learn how Klarity Health’s provider network gives you patient access, regulatory support, and guaranteed ROI — no marketing spend, no platform fees, just appointments when you want them.

👉 Explore Klarity’s Provider Network or Schedule a Call to Learn More

References

1. U.S. Department of Health and Human Services. ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026.’ Press Release. January 2, 2026. https://www

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices